What quality-system certification should buyers verify before purchasing exosome isolation kits?

Buyers should confirm ISO 13485 certification and, for clinical use, CE-IVDR or FDA 510(k) clearance. These certifications ensure manufacturing consistency and lot-to-lot reproducibility [15]. Read More

How do size-exclusion columns compare with ultracentrifugation for clinical-grade purity?

Size-exclusion columns deliver higher purity with less protein contamination in under 30 minutes. Ultracentrifugation remains cheaper per run but introduces vesicle aggregation that reduces downstream analytical accuracy [3]. Read More

What is the typical payback period for an exosome characterization instrument?

Most facilities recover the USD 250,000–400,000 capital outlay within 18–24 months through fee-for-service testing volume. High-throughput labs with 50+ samples per week achieve payback faster [6]. Read More

How does the Exosomes Market address cold-chain logistics for therapeutic-grade vesicles?

Lyophilization and trehalose-based stabilization now allow ambient-temperature shipping for up to 72 hours. These advances reduce logistics costs by approximately 35% compared to cryogenic transport [4]. Read More

Which reimbursement codes currently cover exosome-based diagnostics in the Exosomes Market?

Three Medicare CPT codes introduced in January 2025 cover oncology liquid-biopsy panels using exosomal analytes. Private-payer adoption is expected to follow within 12–18 months [1]. Read More

What intellectual-property barriers exist for new entrants in the Exosomes Market?

Over 4,500 active patent families cover isolation methods, surface engineering, and cargo-loading techniques. Freedom-to-operate analyses typically require 6–9 months and USD 150,000–250,000 in legal costs [14]. Read More

How do exosome therapeutics differ from lipid-nanoparticle delivery systems in clinical performance?

Exosomes exhibit superior blood-brain-barrier permeability and lower immunogenicity than synthetic lipid nanoparticles. However, manufacturing scalability remains a challenge compared to well-established LNP production lines [8]. Read More

Exosomes Market (2025 - 2035)

ID: MRFR/LS/19947-HCR

128 Pages

Nidhi Mandole

Last Updated: July 12, 2026

Exosomes Market Research Report: Size, Share, Trend Analysis By Applications (Drug Delivery, Diagnostics, Therapeutics, Biomarkers), By Source (Bovine, Human, Mouse, Other Mammals), By Isolation Technique (Ultracentrifugation, Filtration, Precipitation, Microfluidics), By End Use (Research Laboratories, Clinical Laboratories, Pharmaceutical Companies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Exosomes Market

Market Size

Forecast Period2025-2035

CAGR (2025-2035)23.5%

2025 Market SizeUSD 0.76 Billion

2035 Market SizeUSD 6.35 Billion

Key Players

Thermo Fisher Scientific

QIAGEN N.V.

System Biosciences

Lonza Group

Miltenyi Biotec

Beckman Coulter

Trends

Liquid-Biopsy Clinical Adoption
Microfluidic Isolation Cost Reduction
GMP Manufacturing Scale-Up

Opportunities

Point-of-Care Exosome Diagnostics
CNS Therapeutic Delivery
Emerging-Market Expansion

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 Liquid-Biopsy Clinical Adoption | |
  2. 3.1.2 Microfluidic Isolation Cost Reduction | |
  3. 3.1.3 GMP Manufacturing Scale-Up | |
  4. 3.1.4 AI-Integrated Multi-Omic Profiling | |
  5. 3.1.5 Regenerative-Medicine Regulatory Pathways | |
  6. 3.1.6 Rising Oncology & CNS Incidence | |
  7. 3.1.7 Venture-Capital Funding Influx |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 Lack of Standardized Isolation Protocols | |
  2. 3.2.2 High Instrument Capital Expenditure | |
  3. 3.2.3 Regulatory Fragmentation Across Jurisdictions | |
  4. 3.2.4 Cargo Contamination & Reproducibility Concerns | |
  5. 3.2.5 Limited Reimbursement Outside Oncology |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 Point-of-Care Exosome Diagnostics | |
  2. 3.3.2 CNS Therapeutic Delivery | |
  3. 3.3.3 Emerging-Market Expansion | |
  4. 3.3.4 Data Monetization through Exosome Biobanking | |
  5. 3.3.5 Veterinary and Agricultural Applications |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Exosomes Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD Billion) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Product | |
  1. 5.1.1 Kits & Reagents | |
  2. 5.1.2 Instruments | |
  3. 5.1.3 Services & Software |
2. 5.2 By Workflow | |
  1. 5.2.1 Isolation Methods | | |
    1. 5.2.1.1 Ultracentrifugation | | |
    2. 5.2.1.2 Size-Exclusion Chromatography | | |
    3. 5.2.1.3 Immunoaffinity Capture | | |
    4. 5.2.1.4 Microfluidic Techniques | | |
    5. 5.2.1.5 Polymer Precipitation | |
  2. 5.2.2 Downstream Analysis |
3. 5.3 By Biomolecule Type | |
  1. 5.3.1 Non-coding RNA | |
  2. 5.3.2 Proteins & Peptides | |
  3. 5.3.3 Lipids | |
  4. 5.3.4 mRNA |
4. 5.4 By Application | |
  1. 5.4.1 Diagnostics | |
  2. 5.4.2 Therapeutics |
5. 5.5 By Source (Cell Type) | |
  1. 5.5.1 MSC-Derived | |
  2. 5.5.2 Tumor Cell-Derived | |
  3. 5.5.3 Immune Cell-Derived | |
  4. 5.5.4 Platelet-Derived |
6. 5.6 By End-User | |
  1. 5.6.1 Pharmaceutical & Biotechnology Companies | |
  2. 5.6.2 Academic & Research Institutes | |
  3. 5.6.3 Hospitals & Clinics
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 United Kingdom | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of MEA
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2025) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 Thermo Fisher Scientific | |
  2. 7.3.2 QIAGEN N.V. | |
  3. 7.3.3 System Biosciences (Bio-Techne) | |
  4. 7.3.4 Lonza Group | |
  5. 7.3.5 Miltenyi Biotec | |
  6. 7.3.6 Beckman Coulter (Danaher) | |
  7. 7.3.7 Izon Science | |
  8. 7.3.8 Fujifilm Holdings | |
  9. 7.3.9 Sartorius AG | |
  10. 7.3.10 NanoFCM Co.
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 AI-Driven Biomarker Discovery |
2. 8.2 Platform Consolidation and Ecosystem Lock-In |
3. 8.3 Regulatory Standardization and GMP Exosomes Market — Table of Contents & Market Segmentation Executive Summary
1 Market Summary
2 Key Report Takeaways
3 Market Size and Forecast (2021–2035)
4 Driver Impact Analysis
5 Restraints Impact Analysis
6 Opportunities
7 Regional Market Share and Country-Level Analysis |
1. 7.1 North America |
2. 7.2 Europe |
3. 7.3 Asia-Pacific |
4. 7.4 South America |
5. 7.5 Middle East & Africa
8 Future Outlook (2026–2035)
9 Market Segmentation Analysis |
1. 5.1 By Product | |
  1. 5.1.1 Kits & Reagents | |
  2. 5.1.2 Instruments | |
  3. 5.1.3 Services & Software |
2. 5.2 By Workflow | |
  1. 5.2.1 Isolation Methods | |
  2. 5.2.2 Downstream Analysis |
3. 5.3 By Biomolecule Type | |
  1. 5.3.1 Non-coding RNA | |
  2. 5.3.2 Proteins & Peptides | |
  3. 5.3.3 Lipids | |
  4. 5.3.4 mRNA |
4. 5.4 By Application | |
  1. 5.4.1 Diagnostics | |
  2. 5.4.2 Therapeutics |
5. 5.5 By Source (Cell Type) | |
  1. 5.5.1 MSC-Derived | |
  2. 5.5.2 Tumor Cell-Derived | |
  3. 5.5.3 Immune Cell-Derived | |
  4. 5.5.4 Platelet-Derived |
6. 5.6 By End-User | |
  1. 5.6.1 Pharmaceutical & Biotechnology Companies | |
  2. 5.6.2 Academic & Research Institutes | |
  3. 5.6.3 Hospitals & Clinics
10 Competitive Landscape
11 Recent News & Developments
12 Report Scope and Methodology
13 Detailed Sources and Citations
14 Frequently Asked Questions
15 LIST OF TABLES |
TABLE 1 Exosomes Market Summary Table |
TABLE 2 Exosomes Market Market Size and Forecast, 2021–2035 |
TABLE 3 Driver Impact Analysis |
TABLE 4 Restraints Impact Analysis |
TABLE 5 Regional Market Share Summary |
TABLE 6 North America Country-Level Analysis |
TABLE 7 Europe Country-Level Analysis |
TABLE 8 Asia-Pacific Country-Level Analysis |
TABLE 9 South America Country-Level Analysis |
TABLE 10 Middle East & Africa Country-Level Analysis |
TABLE 11 Exosomes Market Segmentation by By Product |
TABLE 12 Exosomes Market Segmentation by By Workflow |
TABLE 13 Exosomes Market Segmentation by By Biomolecule Type |
TABLE 14 Exosomes Market Segmentation by By Application |
TABLE 15 Exosomes Market Segmentation by By Source (Cell Type) |
TABLE 16 Exosomes Market Segmentation by By End-User |
TABLE 17 Competitive Benchmarking Matrix |
TABLE 18 Report Scope and Methodology |
TABLE 19 Detailed Sources and Citations
16 LIST OF FIGURES |
FIGURE 1 Exosomes Market Market Size Trend, 2021–2035 |
FIGURE 2 Exosomes Market Year-over-Year Growth Outlook |
FIGURE 3 Regional Revenue Share Analysis |
FIGURE 4 Driver and Restraint Impact Matrix |
FIGURE 5 Competitive Landscape Snapshot |
FIGURE 6 Segment Share by By Product |
FIGURE 7 Segment Share by By Workflow |
FIGURE 8 Segment Share by By Biomolecule Type |
FIGURE 9 Segment Share by By Application |
FIGURE 10 Segment Share by By Source (Cell Type) |
FIGURE 11 Segment Share by By End-User

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Product	Kits & Reagents, Instruments, Services & Software	Kits & Reagents	Instruments
By Workflow	Isolation Methods, Downstream Analysis	Isolation Methods	Downstream Analysis
By Biomolecule Type	Non-coding RNA, Proteins & Peptides, Lipids, mRNA	Non-coding RNA	Proteins & Peptides
By Application	Diagnostics, Therapeutics	Diagnostics	Therapeutics
By Source (Cell Type)	MSC-Derived, Tumor Cell-Derived, Immune Cell-Derived, Platelet-Derived	MSC-Derived	Tumor Cell-Derived
By End-User	Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals & Clinics	Pharmaceutical & Biotechnology Companies	Academic & Research Institutes

Market Segmentation Overview

By Product

Sub-Segment	Key Trend
Kits & Reagents	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.
Instruments	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.
Services & Software	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.

By Product segmentation follows the same taxonomy used in Section 9 of the RD, keeping the TOC and segmentation add-on aligned with the generated report content.

By Workflow

Sub-Segment	Key Trend
Isolation Methods	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.
Downstream Analysis	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.

By Workflow segmentation follows the same taxonomy used in Section 9 of the RD, keeping the TOC and segmentation add-on aligned with the generated report content.

By Biomolecule Type

Sub-Segment	Key Trend
Non-coding RNA	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.
Proteins & Peptides	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.
Lipids	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.
mRNA	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.

By Biomolecule Type segmentation follows the same taxonomy used in Section 9 of the RD, keeping the TOC and segmentation add-on aligned with the generated report content.

By Application

Sub-Segment	Key Trend
Diagnostics	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.
Therapeutics	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.

By Application segmentation follows the same taxonomy used in Section 9 of the RD, keeping the TOC and segmentation add-on aligned with the generated report content.

By Source (Cell Type)

Sub-Segment	Key Trend
MSC-Derived	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.
Tumor Cell-Derived	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.
Immune Cell-Derived	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.
Platelet-Derived	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.

By Source (Cell Type) segmentation follows the same taxonomy used in Section 9 of the RD, keeping the TOC and segmentation add-on aligned with the generated report content.

By End-User

Sub-Segment	Key Trend
Pharmaceutical & Biotechnology Companies	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.
Academic & Research Institutes	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.
Hospitals & Clinics	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.

By End-User segmentation follows the same taxonomy used in Section 9 of the RD, keeping the TOC and segmentation add-on aligned with the generated report content.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”